Immunotherapies are some of the most promising new weapons in the fight against cancer. But are they promising enough to justify their sky-high prices? Payers aren’t convinced, and say they need better data to make effective market access and reimbursement decisions.
FirstWord’s Payer Insight: Cancer Immunotherapy report explains why. This 111-page report gives you an in-depth account of how 12 leading payers in the US and Europe see the cancer immunotherapy landscape.
You’ll discover payers’ top concerns, find out how they assess the value of new cancer immunotherapy drugs, and get their candid thoughts on pricing, reimbursement, market access, and what they expect from pharma companies.
The report also includes analyses of 4 leading approved immunotherapies, and 10 pipeline drugs currently in clinical trials.
Answering key questions:
Get answers to key questions about approved and pipeline immunotherapies:
- Checkpoint Inhibitors: how will competition affect pricing negotiations as late-stage pipeline checkpoint inhibitors come on the market?
- Cancer Vaccines: how will new market entrants escape the shadow of Provenge—a costly early cancer vaccine that overpromised and underdelivered, leaving payers feeling sceptical?
- CD19-targeted CAR-T Treatments: with only preliminary data available, how will payers evaluate these new treatments?
- Combination therapies: how will changes to policy and legislation help payers accommodate complex and extremely costly combination therapies?
- Rising Costs: though promising, cancer immunotherapies are set to increase the already high cost of oncology drugs. Find out how higher costs are straining healthcare systems and challenging payers.
- Restricted Access: high costs are prompting payers in both the US and EU to restrict access to immunotherapies. Find out why payers expect better data and screening techniques to help identify candidates for immunotherapy treatment.
- Effect of Health Reforms: in the EU, healthcare reforms are having a big impact on pricing, reimbursement and market access for expensive treatments. In the US “Obamacare” is expected to have a similar effect. Learn how these reforms affect payer decision-making for cancer immunotherapies.
- Pricing Problems: pharma companies are setting prices for cancer immunotherapies without giving payers the clinical data they need for cost-benefit analyses. Find out how this affects long-term budgeting, and how payers are responding.
- Risk Sharing Too Complex: without the clinical data they need to properly assess risk-sharing, payers are considering other types of agreements for cancer immunotherapies. Find out what those are and how they affect the way new drugs are brought to market.
- Payers Demand Data: payers expect pharma companies to justify the high prices they charge for cancer immunotherapy drugs. That means providing more and better clinical data to help payers make reimbursement and access decisions. Find out what kind of data payers want and why.
|Due to the format and/or brevity of this report, there is no table of contents available.